

Hans Heemskerk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11382343/publications.pdf>

Version: 2024-02-01

11
papers

603
citations

1040056

9
h-index

1372567

10
g-index

11
all docs

11
docs citations

11
times ranked

884
citing authors

#	ARTICLE	IF	CITATIONS
1	The panniculus carnosus muscle: a missing link in the chronicity of heel pressure ulcers?. Journal of the Royal Society Interface, 2022, 19, 20210631.	3.4	4
2	Superpixel-based segmentation of muscle fibers in multi-channel microscopy. BMC Systems Biology, 2016, 10, 124.	3.0	22
3	Peptide Conjugation of 2'-O-methyl Phosphorothioate Antisense Oligonucleotides Enhances Cardiac Uptake and Exon Skipping in mdx Mice. Nucleic Acid Therapeutics, 2014, 24, 25-36.	3.6	52
4	Long-term Exon Skipping Studies With 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models. Molecular Therapy - Nucleic Acids, 2012, 1, e44.	5.1	36
5	Prednisolone Treatment Does Not Interfere with 2'-O-Methyl Phosphorothioate Antisense-Mediated Exon Skipping in Duchenne Muscular Dystrophy. Human Gene Therapy, 2012, 23, 262-273.	2.7	14
6	Identification of Peptides for Tissue-Specific Delivery. Methods in Molecular Biology, 2012, 867, 379-392.	0.9	0
7	Phage display screening without repetitious selection rounds. Analytical Biochemistry, 2012, 421, 622-631.	2.4	149
8	Accurate quantification of dystrophin mRNA and exon skipping levels in Duchenne Muscular Dystrophy. Laboratory Investigation, 2010, 90, 1396-1402.	3.7	37
9	Preclinical PK and PD Studies on 2'-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model. Molecular Therapy, 2010, 18, 1210-1217.	8.2	132
10	Guidelines for Antisense Oligonucleotide Design and Insight Into Splice-modulating Mechanisms. Molecular Therapy, 2009, 17, 548-553.	8.2	125
11	Development of Antisense-Mediated Exon Skipping as a Treatment for Duchenne Muscular Dystrophy. Annals of the New York Academy of Sciences, 2009, 1175, 71-79.	3.8	32